Eledon Pharmaceuticals, Inc. (ELDN) Stock Analysis & Investment Frameworks
Eledon Pharmaceuticals, Inc. (ELDN) stock analysis on Invetso. Review Eledon Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Eledon Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Eledon Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $199.90M
- Revenue: $N/A
- ROE: -136.45%
- ROIC: -73.77%
- Dividend Yield: N/A
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.